Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1975 1
1976 1
1978 1
1980 1
1982 2
1983 1
1984 1
1985 1
1986 1
1989 5
1990 4
1991 1
1992 3
1993 2
1994 7
1995 3
1996 2
1997 6
1998 1
1999 8
2000 15
2001 18
2002 10
2003 15
2004 10
2005 22
2006 11
2007 7
2008 10
2009 12
2010 17
2011 27
2012 21
2013 19
2014 23
2015 12
2016 14
2017 11
2018 23
2019 24
2020 16
2021 21
2022 13
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Results by year

Filters applied: . Clear all
Page 1
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, … See abstract for full author list ➔ Klionsky DJ, et al. Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356. Autophagy. 2016. PMID: 26799652 Free PMC article. No abstract available.
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, Mumtaz M, Olsen PS, Heiser JC, Merhi W, Kleiman NS, Chetcuti SJ, Gleason TG, Lee JS, Cheng W, Makkar RR, Crestanello J, George B, George I, Kodali S, Yakubov SJ, Serruys PW, Lange R, Piazza N, Williams MR, Oh JK, Adams DH, Li S, Reardon MJ; SURTAVI Trial Investigators. Van Mieghem NM, et al. JAMA Cardiol. 2022 Oct 1;7(10):1000-1008. doi: 10.1001/jamacardio.2022.2695. JAMA Cardiol. 2022. PMID: 36001335 Free PMC article. Clinical Trial.

At 5 years, the rates of death or disabling stroke were similar (TAVR, 31.3% vs surgery, 30.8%; hazard ratio, 1.02 [95% CI, 0.85-1.22]; P = .85). Transprosthetic gradients remained lower (mean [SD], 8.6 [5.5] mm Hg vs 11.2 [6.0] mm Hg; P < .001) and aortic valve

At 5 years, the rates of death or disabling stroke were similar (TAVR, 31.3% vs surgery, 30.8%; hazard ratio, 1.02 [95% CI, 0.85-1.22]; P
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier …
At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo gro …
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.
Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, Lang E, Hemmati HD, Chandler SP; CHAMP Trial Group Investigators. Zadnik K, et al. JAMA Ophthalmol. 2023 Oct 1;141(10):990-999. doi: 10.1001/jamaophthalmol.2023.2097. JAMA Ophthalmol. 2023. PMID: 37261839 Free PMC article.
At month 36, compared with placebo, low-dose atropine, 0.02%, did not significantly increase the responder proportion (odds ratio [OR], 1.77; 95% CI, 0.50-6.26; P = .37) or slow mean SER progression (least squares mean [LSM] difference, 0.10 D; 95% CI, -0.02 D to 0.22 D; …
At month 36, compared with placebo, low-dose atropine, 0.02%, did not significantly increase the responder proportion (odds ratio [OR], 1.77 …
Validation of the ^{10}Be Ground-State Molecular Structure Using ^{10}Be(p,palpha)^{6}He Triple Differential Reaction Cross-Section Measurements.
Li PJ, Beaumel D, Lee J, Assié M, Chen S, Franchoo S, Gibelin J, Hammache F, Harada T, Kanada-En'yo Y, Kubota Y, Leblond S, Liang PF, Lokotko T, Lyu M, Marqués FM, Matsuda Y, Ogata K, Otsu H, Rindel E, Stuhl L, Suzuki D, Togano Y, Tomai T, Xu XX, Yoshida K, Zenihiro J, Achouri NL, Aumann T, Baba H, Cardella G, Ceruti S, Stefanescu AI, Corsi A, Frotscher A, Gao J, Gillibert A, Inaba K, Isobe T, Kawabata T, Kitamura N, Kobayashi T, Kondo Y, Kurihara A, Liu HN, Miki H, Nakamura T, Obertelli A, Orr NA, Panin V, Sasano M, Shimada T, Sun YL, Tanaka J, Trache L, Tudor D, Uesaka T, Wang H, Yamada H, Yang ZH, Yasuda M. Li PJ, et al. Phys Rev Lett. 2023 Nov 24;131(21):212501. doi: 10.1103/PhysRevLett.131.212501. Phys Rev Lett. 2023. PMID: 38072612
The cluster structure of the neutron-rich isotope ^{10}Be has been probed via the (p,palpha) reaction at 150 MeV/nucleon in inverse kinematics and in quasifree conditions. ...The triple differential cross section for the ground-state transition was extracted for quasifree …
The cluster structure of the neutron-rich isotope ^{10}Be has been probed via the (p,palpha) reaction at 150 MeV/nucleon in inverse k …
Continuous-wave upconverting nanoparticle microlasers.
Fernandez-Bravo A, Yao K, Barnard ES, Borys NJ, Levy ES, Tian B, Tajon CA, Moretti L, Altoe MV, Aloni S, Beketayev K, Scotognella F, Cohen BE, Chan EM, Schuck PJ. Fernandez-Bravo A, et al. Nat Nanotechnol. 2018 Jul;13(7):572-577. doi: 10.1038/s41565-018-0161-8. Epub 2018 Jun 18. Nat Nanotechnol. 2018. PMID: 29915271
Indefinite and bidirectional near-infrared nanocrystal photoswitching.
Lee C, Xu EZ, Kwock KWC, Teitelboim A, Liu Y, Park HS, Ursprung B, Ziffer ME, Karube Y, Fardian-Melamed N, Pedroso CCS, Kim J, Pritzl SD, Nam SH, Lohmueller T, Owen JS, Ercius P, Suh YD, Cohen BE, Chan EM, Schuck PJ. Lee C, et al. Nature. 2023 Jun;618(7967):951-958. doi: 10.1038/s41586-023-06076-7. Epub 2023 May 31. Nature. 2023. PMID: 37258675
A few-layer covalent network of fullerenes.
Meirzadeh E, Evans AM, Rezaee M, Milich M, Dionne CJ, Darlington TP, Bao ST, Bartholomew AK, Handa T, Rizzo DJ, Wiscons RA, Reza M, Zangiabadi A, Fardian-Melamed N, Crowther AC, Schuck PJ, Basov DN, Zhu X, Giri A, Hopkins PE, Kim P, Steigerwald ML, Yang J, Nuckolls C, Roy X. Meirzadeh E, et al. Nature. 2023 Jan;613(7942):71-76. doi: 10.1038/s41586-022-05401-w. Epub 2023 Jan 4. Nature. 2023. PMID: 36600065
404 results